Significant benefits of adding neoadjuvant chemotherapy before concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis of randomized controlled trials.
about
The impacts of single nucleotide polymorphisms in genes of cell cycle and NF-kB pathways on the efficacy and acute toxicities of radiotherapy in patients with nasopharyngeal carcinomaA retrospective paired study: efficacy and toxicity of nimotuzumab versus cisplatin concurrent with radiotherapy in nasopharyngeal carcinoma.Feasibility of concurrent chemoradiotherapy with high-dose cisplatin after induction TPF chemotherapy in head and neck cancer: a critical review of the literature and the experience of the European Institute of Oncology.Genetic polymorphisms of Wnt/β-catenin pathway genes are associated with the efficacy and toxicities of radiotherapy in patients with nasopharyngeal carcinoma.Induction Chemotherapy plus Concurrent Chemoradiotherapy vs Concurrent Chemoradiotherapy in Elderly Patients with Advanced Nasopharyngeal Carcinoma.Unidimensional measurement may be superior to assess primary tumor response after neoadjuvant chemotherapy for nasopharyngeal carcinoma.Association between VEGF-460T/C gene polymorphism and clinical outcomes of nasopharyngeal carcinoma treated with intensity-modulated radiation therapy.Efficacy and safety of nimotuzumab with neoadjuvant chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma.Association of the neoadjuvant chemotherapy cycle with survival outcomes in patients with locoregionally advanced nasopharyngeal carcinoma: a propensity-matched analysis.Practice patterns for the radical treatment of nasopharyngeal cancer by head and neck oncologists in the United Kingdom.Addition of 5-fluorouracil to docetaxel/cisplatin does not improve survival in locoregionally advanced nasopharyngeal carcinoma.Additional induction chemotherapy to concurrent chemotherapy and intensity-modulated radiotherapy with or without nimotuzumab in first-line treatment for locoregionally advanced nasopharyngeal carcinoma: a propensity score matched analysis.Addition of chemotherapy to intensity-modulated radiotherapy does not improve survival in stage II nasopharyngeal carcinoma patients.
P2860
Q33648870-5D15E58D-E328-4A81-8C00-CDC5CCBAF7C7Q36220797-B981CB1A-BBB9-4FD6-9321-D3ADEBC425F0Q36341166-E2E9B0C8-F122-409B-864B-5A5B42FCAD07Q37696169-2BAFB52A-7DE6-498E-A406-D6B72EDCAB42Q40238608-27DFA815-87E9-4F5E-83BC-254A904D62F1Q41470825-C252AB01-628E-47AD-8C0A-4EBF625E090FQ41991817-744EA041-C615-407A-B67A-6C6B07DFF05FQ45357051-CB7250F0-6D6C-46F0-8F54-EEFB896C471DQ47098637-E1BD5C71-FD22-46B2-86AF-C797C2145F7FQ48185045-EB950E6B-2ABB-4A93-86C3-796B3B679DBAQ48502128-5B64C356-97D9-4031-9D06-355D14C9F0E7Q50311224-F85B7C28-7659-48FE-BBAF-D420F42B79E5Q55259880-90BB44C2-B2C8-4E88-9FB3-92A557FD9406
P2860
Significant benefits of adding neoadjuvant chemotherapy before concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis of randomized controlled trials.
description
2016 nî lūn-bûn
@nan
2016 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Significant benefits of adding ...... randomized controlled trials.
@ast
Significant benefits of adding ...... randomized controlled trials.
@en
type
label
Significant benefits of adding ...... randomized controlled trials.
@ast
Significant benefits of adding ...... randomized controlled trials.
@en
prefLabel
Significant benefits of adding ...... randomized controlled trials.
@ast
Significant benefits of adding ...... randomized controlled trials.
@en
P2093
P2860
P356
P1433
P1476
Significant benefits of adding ...... randomized controlled trials.
@en
P2093
Huimin Tian
Jiuwei Cui
Mengmeng Wang
Tingwen Ge
P2860
P304
48375-48390
P356
10.18632/ONCOTARGET.10237
P407
P577
2016-06-23T00:00:00Z